Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Craig I. Coleman, Christopher Baugh, Concetta Crivera, Dejan Milentijevic, Sheng-Wei Wang, Lang Lu & Winnie W. Nelson. (2017) Healthcare costs associated with rivaroxaban or warfarin use for the treatment of venous thromboembolism. Journal of Medical Economics 20:2, pages 200-203.
Read now
Read now
Articles from other publishers (17)
Xian Pu, Yun Tao, Jienan Lou, Guanglei Lu, Haoran Xu, Shuming Tan & Guofang Xie. (2023) Flavonoids extract from Rosa roxburghii fruit ameliorates carrageenan-induced thrombosis in mice. Journal of Functional Foods 109, pages 105785.
Crossref
Crossref
Albert A. Volkl, Kenneth Todd Moore, Lloyd Haskell & Elliot S. Barnathan. (2023) Updated Renal Dosage Recommendations for Rivaroxaban in Patients Experiencing or at Risk of Thromboembolic Disease. American Journal of Cardiovascular Drugs 23:3, pages 247-255.
Crossref
Crossref
Mashio Nakamura, Ikuo Fukuda, Norikazu Yamada, Morimasa Takayama, Hideaki Maeda, Takeshi Yamashita, Takanori Ikeda, Makoto Mo, Tsutomu Yamazaki, Yasuo Okumura & Atsushi Hirayama. (2023) Duration of Initial Intensive Rivaroxaban Therapy for Patients With Venous Thromboembolism ― Subanalysis of the J’xactly Study ―. Circulation Reports 5:4, pages 144-151.
Crossref
Crossref
Victoria R Nachar & Allison J Schepers. (2021) Clinical controversies in the treatment of cancer-associated venous thromboembolism. Journal of Oncology Pharmacy Practice 27:4, pages 939-953.
Crossref
Crossref
Kensuke Takeuchi. (2020) Anticoagulation Using Rivaroxaban for VTE Treatment: Dose Adjustment According to Thrombus VolumeVTEに対するリバーロキサバンによる抗凝固療法—用量別の治療成績についての後方視的検討—. The Japanese Journal of Phlebology 31:3, pages 89-93.
Crossref
Crossref
Behnood Bikdeli, Carmen Rodríguez, Alberto García-Ortega & David Jiménez. 2020. Cardiovascular Complications of Respiratory Disorders. Cardiovascular Complications of Respiratory Disorders
184
197
.
Derek Weycker, Gail DeVecchis WygantJennifer D. GuoTheodore LeeXuemei Luo, Lisa RosenblattJack MardekianMark AtwoodAhuva Hanau & Alexander T. Cohen. (2020) Bleeding and recurrent VTE with apixaban vs warfarin as outpatient treatment: time-course and subgroup analyses. Blood Advances 4:2, pages 432-439.
Crossref
Crossref
Li Wang, Onur Baser, Phil Wells, W. Frank Peacock, Craig Coleman, Gregory Fermann, Jeff Schein & Concetta Crivera. (2019) Predictors of Hospital Length of Stay among Patients with Low-risk Pulmonary Embolism. Journal of Health Economics and Outcomes Research, pages 84-94.
Crossref
Crossref
Li Wang, Onur Baser, Phil Wells, W. Frank Peacock, Craig I. Coleman, Gregory J. Fermann, Jeff Schein & Concetta Crivera. (2019) Predictors of Hospital Length of Stay among Patients with Low-risk Pulmonary Embolism. Journal of Health Economics and Outcomes Research 6:2, pages 84-94.
Crossref
Crossref
Jeffrey S. Berger, Roger Seheult, François Laliberté, Concetta Crivera, Dominique Lejeune, Yongling Xiao, Jeff Schein, Patrick Lefebvre & Scott Kaatz. (2018) Clinical outcomes of prolonged anticoagulation with rivaroxaban after unprovoked venous thromboembolism. Research and Practice in Thrombosis and Haemostasis 2:1, pages 58-68.
Crossref
Crossref
Li Wang, Onur Baser, Phil Wells, W. Frank Peacock, Craig I. Coleman, Gregory J. Fermann, Jeff Schein & Concetta Crivera. (2017) Overall Effectiveness of Rivaroxaban in Patients with Pulmonary Embolism. Clinical Therapeutics 39:7, pages 1426-1436.e2.
Crossref
Crossref
Alok A. Khorana, Keith R. McCrae, Dejan Milentijevic, Jonathan Fortier, Winnie W. Nelson, François Laliberté, Concetta Crivera, Patrick Lefebvre, Daniel Yannicelli & Jeff Schein. (2017) Current practice patterns and patient persistence with anticoagulant treatments for cancer‐associated thrombosis. Research and Practice in Thrombosis and Haemostasis 1:1, pages 14-22.
Crossref
Crossref
Craig I. Coleman, Thomas J. Bunz & Alexander G. G. Turpie. (2017) Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism. Thrombosis and Haemostasis 117:10, pages 1841-1847.
Crossref
Crossref
Steven Deitelzweig, François Laliberté, Concetta Crivera, Guillaume Germain, Brahim K. Bookhart, William H. Olson, Jeffrey Schein & Patrick Lefebvre. (2016) Hospitalizations and Other Health Care Resource Utilization Among Patients with Deep Vein Thrombosis Treated with Rivaroxaban Versus Low-molecular-weight Heparin and Warfarin in the Outpatient Setting. Clinical Therapeutics 38:8, pages 1803-1816.e3.
Crossref
Crossref
Jir Ping Boey & Alexander Gallus. (2016) Drug Treatment of Venous Thromboembolism in the Elderly. Drugs & Aging 33:7, pages 475-490.
Crossref
Crossref
Gary E. Raskob, Alex S. Gallus, Paul Sanders, John R. Thompson, Giancarlo Agnelli, Harry R. Buller, Alexander T. Cohen, Eduardo Ramacciotti & Jeffrey I. Weitz. (2017) Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. Thrombosis and Haemostasis 115:04, pages 809-816.
Crossref
Crossref
Elizabeth S. Mearns, Christine G. Kohn, Ju-Sung Song, Jessica Hawthorne, Joy Meng, C. Michael White, Monika K. Raut, Jeff R. Schein & Craig I. Coleman. (2014) Meta-Analysis to Assess the Quality of International Normalized Ratio Control and Associated Outcomes in Venous Thromboembolism Patients. Thrombosis Research 134:2, pages 310-319.
Crossref
Crossref